CAR T Cell: Do Benefits Still Outweigh Risks? CAR T Cell: Do Benefits Still Outweigh Risks?
Despite concerns about the development of secondary T-cell malignancies due to CAR T-cell immunotherapy, experts still believed that the benefits outweigh the risks.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Development of CAR-T Cells for T-ALL Targeting CCR9, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL). CCR9 is a potential cancer immunotherapy target, expressed in the majority of cases of T-ALL but... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2024 Category: Pharmaceuticals Tags: FVT TRI Source Type: news
Immunotherapy May Hold Promise for Skin Cancers After Kidney Transplant
(MedPage Today) -- The use of immune checkpoint inhibitors given as part of an immunosuppressive regimen for kidney transplant recipients with advanced cutaneous cancers may be effective and safe, depending on the regimen, two small studies suggested... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 14, 2024 Category: Dermatology Source Type: news
Immune-Related AEs Predict Outcomes in Advanced GU Cancers Immune-Related AEs Predict Outcomes in Advanced GU Cancers
Patients with advanced GU cancers who had immune-related AEs from immunotherapy had better overall survival — a phenomenon also reported for other cancer types.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Baked Milk Oral Immunotherapy Found to be Effective Treatment for Cow's Milk Allergy
Research shows after 12 and 24 months of treatment, participants experienced significant desensitization to milk products MILWAUKEE, Feb. 7, 2024 /PRNewswire-PRWeb/ -- Baked milk oral immunotherapy (BMOIT) is well tolerated and induces substantial desensitization to both baked and... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 7, 2024 Category: Pharmaceuticals Tags: TRI FVT CHI Source Type: news
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today…#gaithersburg #neximmune #hcwainwrightco #forms3 #llc #430parkavenue #3rdfloor #section4a2 #securitiesact #aim (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2024 Category: Consumer Health News Source Type: news
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
Bria-Pros+ is based on BriaCell's next generation personalized immunotherapy platform • Bria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells and natural killer cells PHILADELPHIA and VANCOUVER, British Columbia, Feb. 06, 2024…#briacell #briapros #philadelphia #britishcolumbia #gmp #sitc #williamvwilliams #hla #classicalnk #nkt (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2024 Category: Consumer Health News Source Type: news
Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy
FRIDAY, Feb. 2, 2024 -- The incidence of secondary primary malignancy after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy is very low, according to a study published online Jan. 24 in Nature Medicine.Guido Ghilardi, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 2, 2024 Category: Pharmaceuticals Source Type: news
' Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer
KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Small PFS Gain in Metastatic Prostate Cancer With TKI, ICI Small PFS Gain in Metastatic Prostate Cancer With TKI, ICI
Men with metastatic castration-resistant prostate cancer had a slight but significant improvement in progression-free survival with a TKI plus immunotherapy vs hormonal therapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news
Early Mesothelioma Vaccine Testing Shows Promise
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Early Mesothelioma Vaccine Testing Shows Survival Gains
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Phase I Trial Improves Mesothelioma Survival More Than 200%
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
